Infliximab(anti human TNF alfa monoclonal antibody, Remicade) off-label treatment for refractory Kawasaki disease
Not Applicable
- Conditions
- Kawasaki disease
- Registration Number
- JPRN-UMIN000007423
- Lead Sponsor
- Department of Pediatrics, Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
congestive heart failure, severe infection, active tuberculosis, hypersensitivity for mouse-derived protein, demyelinating decease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Coronary artery abnormality after infliximab treatment
- Secondary Outcome Measures
Name Time Method duration of fever